Focusing on unmet clinical needs, we collaborate with global biotech /biopharma to jointly develop first- or best-in-class* products. To make the most of respective strengths and improve the efficiency of innovative drug research and development, CMS can/will take on responsibility for clinical development and commercialization in China or specific markets.
*Best-in-class: innovative products with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems
Innovative Pipeline Products
Ongoing Clinical Trials, Mostly are Registrational Randomized Controlled Trials (RCTs)
NDAs in China
*As at 31 December 2022
We acquire innovative products that are in the mid- and late-phase of clinical development or have been approved for marketing. CMS is responsible for clinical development, registration and commercialization of products in China and other authorized countries/regions, in order to improve the patient access of innovative medicine.
CMS is responsible for clinical development, registration and commercialization in China and other authorized countries/regions. This allows the biotech companies to focus on drug discovery and preclinical studies, thereby improving R&D efficiency and accelerate the commercialization of domestic innovative products.
For novel or popular targets in our therapeutic fields of focus, CMS uses CROs to conduct preclinical studies, and manages the entire life cycle of innovative medicines itself, whilst also giving CMS ownership of the product rights globally.
We have established an in-house clinical development system focused on the four key components: medical, clinical, pharmacovigilance and quality assurance. The process is overseen to provide high-level confidence that the medical strategy is rational, clinical operations are effective and compliant, and product safety risks are controllable.
Proven clinical enrollment capability:
*Tildrakizumab Solution for Injection- Completed enrollment of all the 220 subjects within 2.5 months (including the Chinese Spring Festival holidays)
*Cyclosporine Eye Drops 0.09%- Completed enrollment of all the 384 subjects within 4 months (including the Chinese Spring Festival holidays)
*Methylthioninium Chloride Enteric-coated Sustained-release Tablets- Completed enrollment of all the 1,800 subjects within 6 months (including the Chinese Spring Festival holidays)